Related Experiment Video
Updated: May 23, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial
Thi Yen Loan Le1, Mahidi Mardini, Viive M Howell
1Department of Cardiology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Insights
Low-dose mineralocorticoid receptor antagonists protect the heart by preventing cardiomyocyte death and reducing infarct size. These drugs work by preserving the apoptosis repressor with caspase recruitment domain, a key protein in regulating cell death pathways.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pharmacology
Background:
- Mineralocorticoid receptor antagonists (MRAs) are vital in treating heart failure and myocardial infarction.
- Apoptosis significantly contributes to cardiac dysfunction and post-infarction remodeling.
- The role of MRAs in modulating cardiomyocyte apoptosis, particularly via the apoptosis repressor with caspase recruitment domain (ARC), remains under investigation.
Purpose of the Study:
- To investigate whether low-dose MRAs can prevent cardiomyocyte apoptosis by regulating ARC.
- To determine the effect of MRAs on infarct size and cardiac remodeling following ischemia-reperfusion injury.
- To elucidate the molecular mechanisms by which MRAs influence ARC stability and apoptosis.
Main Methods:
- Ex vivo rat heart model subjected to regional ischemia and reperfusion.
- Administration of low-dose spironolactone or eplerenone.
- Assessment of infarct size, apoptosis markers (caspase activation, DNA fragmentation), and ARC protein levels.
- In vitro studies using H9c2 cells to examine aldosterone-induced apoptosis and ARC degradation.
Main Results:
- Low-dose spironolactone and eplerenone significantly reduced infarct size in the ex vivo heart model.
- MRAs prevented ischemia-reperfusion-induced activation of caspases 2, 3, and 9, and abrogated DNA fragmentation.
- MRAs preserved ARC protein levels, inhibited aldosterone-induced ARC degradation, and reduced cardiomyocyte apoptosis.
- Aldosterone promotes ARC degradation via the ubiquitin-proteasomal pathway, a process inhibited by MRAs.
Conclusions:
- Low-dose MRAs effectively reduce myocardial infarct size and apoptosis in a post-ischemia/reperfusion setting.
- The cardioprotective effects of MRAs are mediated, at least in part, by preventing ARC degradation and subsequent cardiomyocyte death.
- These findings highlight a novel mechanism for MRA action in cardiovascular disease, targeting the intrinsic apoptotic pathway via ARC stabilization.
Abstract:
Low-dose mineralocorticoid receptor antagonists reduce morbidity and mortality in patients with heart failure and myocardial infarction, despite normal plasma aldosterone levels. Since apoptosis plays an important role in heart failure and postinfarction left ventricular remodeling, we examined whether low-dose mineralocorticoid receptor antagonists modulate cardiomyocyte death by regulating the apoptosis repressor protein apoptosis repressor with caspase recruitment domain to lessen the extent of apoptosis. Hearts from adult male Sprague-Dawley rats were subjected to regional ischemia followed by reperfusion ex vivo, with mineralocorticoid receptor antagonists added to perfusates before ischemia. Low-dose spironolactone (10 nmol/L) or eplerenone (100 nmol/L) significantly reduced infarct size. Spironolactone also prevented cleavage of the apoptotic chromatin condensation inducer in the nucleus and of the inhibitor of caspase-activated DNAse induced by ischemia-reperfusion, thereby abolishing chromatin condensation and internucleosomal cleavage. Ischemia-reperfusion-induced activation of caspases 2, 3, and 9, but not caspase 8, was prevented by spironolactone, suggesting targeted regulation of the intrinsic pathway. Low-dose spironolactone and eplerenone prevented loss of the apoptosis repressor with the caspase recruitment domain and reduced myocyte death. In H9c2 cells, mineralocorticoid receptor activation by aldosterone resulted in apoptosis repressor with caspase recruitment domain degradation and enhanced apoptosis; these actions were prevented by coadministration of spironolactone. Using a triple lysine mutant we identified that aldosterone enhances posttranscriptional degradation of the apoptosis repressor with a caspase recruitment domain via the ubiquitin-proteasomal pathway. Our data demonstrate that low-dose mineralocorticoid receptor antagonists reduce infarct size and apoptosis in the reperfused myocardium by preventing the apoptosis repressor with caspase recruitment domain degradation.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
